lifestyle.digitaladblog.com

Author: Immutep Limited

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

April 22, 2026
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

April 15, 2026
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

March 19, 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

March 13, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

February 12, 2026
Immutep Quarterly Activities Report Q2 FY26

January 29, 2026